IL228224A - Methods for predicting gastroenteropancreatic neuroendocrine neoplasms (gep-nens) - Google Patents

Methods for predicting gastroenteropancreatic neuroendocrine neoplasms (gep-nens)

Info

Publication number
IL228224A
IL228224A IL228224A IL22822413A IL228224A IL 228224 A IL228224 A IL 228224A IL 228224 A IL228224 A IL 228224A IL 22822413 A IL22822413 A IL 22822413A IL 228224 A IL228224 A IL 228224A
Authority
IL
Israel
Prior art keywords
nens
gep
predicting
methods
gastroenteropancreatic neuroendocrine
Prior art date
Application number
IL228224A
Other languages
Hebrew (he)
Other versions
IL228224A0 (en
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IL228224A0 publication Critical patent/IL228224A0/en
Publication of IL228224A publication Critical patent/IL228224A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL228224A 2011-03-01 2013-09-01 Methods for predicting gastroenteropancreatic neuroendocrine neoplasms (gep-nens) IL228224A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448137P 2011-03-01 2011-03-01
PCT/US2012/027351 WO2012119013A1 (en) 2011-03-01 2012-03-01 PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs)

Publications (2)

Publication Number Publication Date
IL228224A0 IL228224A0 (en) 2013-12-31
IL228224A true IL228224A (en) 2017-11-30

Family

ID=45852725

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228224A IL228224A (en) 2011-03-01 2013-09-01 Methods for predicting gastroenteropancreatic neuroendocrine neoplasms (gep-nens)

Country Status (14)

Country Link
US (1) US9988684B2 (en)
EP (1) EP2681333B1 (en)
JP (2) JP6159662B2 (en)
KR (2) KR102114412B1 (en)
CN (1) CN103502473B (en)
AU (2) AU2012223288B2 (en)
CA (1) CA2828878C (en)
DK (1) DK2681333T3 (en)
ES (1) ES2656487T3 (en)
IL (1) IL228224A (en)
MX (1) MX351779B (en)
PL (1) PL2681333T3 (en)
WO (1) WO2012119013A1 (en)
ZA (1) ZA201306686B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104885090A (en) * 2012-10-09 2015-09-02 凡弗3基因组有限公司 Systems and methods for tumor clonality analysis
ES2881474T3 (en) * 2014-09-15 2021-11-29 Clifton Life Sciences LLC Compositions, methods and kits for the diagnosis of a gastroenteropancreatic neuroendocrine neoplasia
CN107194137B (en) * 2016-01-31 2023-05-23 北京万灵盘古科技有限公司 Necrotizing enterocolitis classification prediction method based on medical data modeling
CN105938521A (en) * 2016-07-04 2016-09-14 苏州大学附属儿童医院 Ankylosing spondylitis forewarning model establishing method and device
WO2018160925A1 (en) * 2017-03-02 2018-09-07 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
WO2018214249A1 (en) * 2017-05-22 2018-11-29 立森印迹诊断技术(无锡)有限公司 Imprinted gene grading model, system composed of same, and application of same
KR20200092382A (en) 2017-11-30 2020-08-03 리퀴드 바이옵시 리서치 엘엘씨 Prediction of peptide receptor radiotherapy using gene expression assays
US20200400687A1 (en) * 2017-12-19 2020-12-24 Chase Therapeutics Corporation Methods for developing pharmaceuticals for treating neurodegenerative conditions
CN108048564B (en) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 New application of human GLT8D1 gene
JP7061768B2 (en) * 2018-03-09 2022-05-02 国立大学法人 東京大学 Biological response analysis method, analysis program, and analysis device
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
WO2019226035A1 (en) * 2018-05-25 2019-11-28 주식회사 엠디헬스케어 Method for diagnosing colon cancer through qpcr analysis
KR102141246B1 (en) * 2018-05-25 2020-08-04 주식회사 엠디헬스케어 Method for the diagnosis of colon cancer using analysis of qPCR
JP7133411B2 (en) 2018-09-19 2022-09-08 テルモ株式会社 CTC collection system and method of operating CTC collection system
CN109190713A (en) * 2018-09-29 2019-01-11 王海燕 The minimally invasive fast inspection technology of oophoroma based on serum mass spectrum adaptive sparse feature selecting
US11875903B2 (en) 2018-12-31 2024-01-16 Tempus Labs, Inc. Method and process for predicting and analyzing patient cohort response, progression, and survival
AU2019418813A1 (en) 2018-12-31 2021-07-22 Tempus Ai, Inc. A method and process for predicting and analyzing patient cohort response, progression, and survival
CN109652550B (en) * 2019-01-21 2022-08-02 首都医科大学附属北京朝阳医院 Application of circ-HUWE1 as diagnosis biomarker and treatment target of gastric cancer and colorectal cancer
CN109949268A (en) * 2019-01-24 2019-06-28 郑州大学第一附属医院 A kind of hepatocellular carcinoma level of differentiation stage division based on machine learning
US11995127B2 (en) * 2019-04-02 2024-05-28 Aspentech Corporation Validation of operating plans and schedules using machine learning
TW202128995A (en) 2019-10-10 2021-08-01 聖克里斯多福商液態生物檢體研究公司 Compositions, methods and kits for biological sample and rna stabilization
WO2022026642A2 (en) * 2020-07-29 2022-02-03 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
KR102519913B1 (en) * 2021-06-15 2023-04-10 재단법인 아산사회복지재단 Biomarker Composition for Diagnosis Pancreas NeuroEndocrine Tumor and Method of providing information for diagnosis of Pancreas NeuroEndocrine Tumor using the same
KR102438608B1 (en) * 2021-06-15 2022-08-31 재단법인 아산사회복지재단 Biomarker Composition for Differential Diagnosis Pancreas NeuroEndocrine Tumor and Method of providing information for Differential diagnosis of Pancreas NeuroEndocrine Tumor using the same
CN113637750A (en) * 2021-07-16 2021-11-12 宁波市第一医院 Auxiliary diagnosis, prognosis diagnosis or risk stratification marker for acute myeloid leukemia and application thereof
WO2024073652A1 (en) * 2022-09-30 2024-04-04 Liquid Biopsy Research LLC Methods for neuroendocrine cancer detection in saliva

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2005020795A2 (en) * 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis

Also Published As

Publication number Publication date
CA2828878C (en) 2020-08-25
CN103502473B (en) 2016-03-09
MX2013010035A (en) 2014-08-27
US9988684B2 (en) 2018-06-05
AU2012223288A1 (en) 2013-09-19
PL2681333T3 (en) 2018-03-30
CA2828878A1 (en) 2012-09-07
US20140066328A1 (en) 2014-03-06
JP6321233B2 (en) 2018-05-09
JP2017104116A (en) 2017-06-15
ES2656487T3 (en) 2018-02-27
KR102114412B1 (en) 2020-06-18
CN103502473A (en) 2014-01-08
KR20180116483A (en) 2018-10-24
KR20140042793A (en) 2014-04-07
EP2681333A1 (en) 2014-01-08
JP6159662B2 (en) 2017-07-05
KR102023584B1 (en) 2019-09-24
ZA201306686B (en) 2015-03-25
EP2681333B1 (en) 2017-11-15
JP2014512172A (en) 2014-05-22
AU2017204086B2 (en) 2019-05-16
AU2012223288B2 (en) 2017-03-30
DK2681333T3 (en) 2018-01-08
MX351779B (en) 2017-10-27
WO2012119013A1 (en) 2012-09-07
AU2017204086A1 (en) 2017-07-06
IL228224A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
IL228224A (en) Methods for predicting gastroenteropancreatic neuroendocrine neoplasms (gep-nens)
HK1249176A1 (en) Method for detecting nucleosome adducts
EP3425063C0 (en) Methods for analyte detection
HUE058093T2 (en) Method for screening alpha-amylases
EP2768983A4 (en) Analysis methods
EP2775294A4 (en) Deterioration analyzing method
EP2637017A4 (en) Filling-capacity measuring method
IL222533A0 (en) Methods for detecting antibodies
EP2650276A4 (en) Method for producing -fluoroalcohol
SG10201600144YA (en) Method for detecting protein-protein interaction
EP2791653A4 (en) Techniques for optimized scatterometry
EP2691544A4 (en) Method for verifying bioassay samples
ZA201400772B (en) Method for using vinasse
EP2726839A4 (en) Sampler
EP2685257A4 (en) Analysis method
EP2752655A4 (en) Method for detecting target particles
EP2762873A4 (en) Method for specifically detecting test substance
GB201120317D0 (en) Screening method
EP2751560A4 (en) Detection method using colorimetric analysis
EP2740803A4 (en) Method for detecting novel fgfr4 mutant
AP2013007021A0 (en) Method for assaying hydrocarbons
EP2751278A4 (en) Method for hydrogen sulfide detection
EP2758778A4 (en) Screening method
EP2725347A4 (en) Method for detecting target particles
EP2743682A4 (en) Method for detecting target particles

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed